Like this:

Local biotech Isis Pharmaceuticals reports strong results for their cholesterol therapy mipomersen, at the same time broadening potential patients from those that are homozygous for familial hypercholesterolemia to those who are heterozygous as well. Isis and partner Genzyme plan to move this treatment to market in 2011.

http://www.xconomy.com/boston/2010/02/10/genzyme-and-isis-report-positive-results-for-cholesterol-lowering-drug/

Advertisement